BioProcess International
Scaling China's biomanufacturing to meet global biologics/biopharmaceutical demand
Tackle the technical and strategic challenges reshaping bioprocessing.
Part of ChinaBio™ expanded content summits
April 27 - 29, 2027 - Shanghai, China
Your first look at the ChinaBio™ preliminary agenda
The preliminary agenda for BioProcess International at ChinaBio™ is packed with new sessions covering the topics shaping the industry right now, from scale-up and process development strategies to CDMO partnerships, regulatory shifts, and the technologies driving next-generation manufacturing in China.
Two decades of bioprocessing expertise, now in Shanghai
For more than 20 years, BioProcess International has brought together the scientists and engineers who make biologics. In 2027, BioProcess International comes to ChinaBio™ with a program built for the moment China’s biomanufacturing community is facing: every molecule licensed to a global partner now needs a CMC package that partner can file, inspect and supply.
Get access to three of the most talked-about sessions from our flagship Boston event, featuring some of the field's leading voices in integrated continuous purification, predictive analytics and advanced process control, and AI and ML in process development. Watch these sessions for free & get a preview of the program content coming to BPI China at ChinaBio™.
Kevin Brower - Global Head of Purification Development at Sanofi
Process Intensification Leveraging Integrated Continuous Purification and Pionic – From Vision to Reality
Preeya Boppana - Director Manufacturing Science & Technology at AstraZeneca
Transforming Biologics Manufacturing: Leveraging Predictive Analytics and Advanced Process Control for Next-Generation Operations
Sarwat Khattak - Head of Cell Culture and Cell Line Development at Biogen
What We have Learned and Also Refined by Using AI and ML in Upstream Process Development
Mapping the road from process development to global supply
Dive deeper into every stage of biologics manufacturing, with a focus on the challenges facing China's biopharma companies today.
Pre-Conference Workshop: Deal-Ready CMC
A hands-on session on building a dual-filing NMPA/FDA/EMA CMC package that survives partner due diligence, including a mock due-diligence review.
Plenary: Built in China, Trusted Globally
Keynotes from China’s leading innovators and regulators on global-quality manufacturing, plus a panel on supply resilience, dual sourcing and segmented production after BIOSECURE.Discover cutting-edge R&D developments including, in vivo CAR-T, solid tumours, and new therapeutic modalities expanding treatments to broader populations
Cell Culture and Upstream Processing
Raise titers and cut costs under China’s price pressure, with sessions on domestic media, difficult-to-express proteins, perfusion and N-1 intensificationUnlock actionable insights from real-world case studies to enhance manufacturing efficiency and reduce costs for autologous, allogeneic, and AAV therapies
Overcoming the Bottlenecks in Downstream Processing
Purify complex bispecifics and trispecifics, run connected downstream processes, and build one viral-clearance data package for NMPA, FDA and EMA.
Intensified and Continuous Processing
Learn how continuous manufacturing and intensified fed-batch are cutting cost of goods, with case studies from companies running them today.Attain clarity on USA, EU, and China frameworks to accelerate approvals worldwide
Digital, AI and PAT in Biomanufacturing
See where AI is paying off across R&D, manufacturing and QC, and how automation and data are building the next generation of plants.
Why China is where global biomanufacturing is being decided
China has become one of the world’s largest sources of new biologics. The question global partners now ask is not whether Chinese molecules work, but whether they can be manufactured, documented and supplied to global standards. BPI China is where that question gets answered.
Record global demand for China-born medicines
Chinese companies signed US$135.7 billion in out-licensing deals in 2025, more than double the year before. Every one of those assets needs a CMC package a global partner can file.
Complex modalities are taking over the pipeline
Bispecifics, multispecifics and ADCs now make up most new biologics projects in China, bringing new challenges in mispairing, conjugation, purification and control strategy.With over 1,000 active cell and gene therapy clinical trials in China alone, offering unprecedented access to innovation pipelines and research partnerships.
Faster regulators, higher expectations
NMPA’s 30-working-day IND pathway, segmented-production pilots and the 2025 Chinese Pharmacopoeia are speeding up development, while BIOSECURE puts dual sourcing and supply-chain traceability at the top of every partner’s checklist.
What does BioProcess International at ChinaBio™ have for YOU?
Whether you are scaling a molecule for its first global filing or looking for the partners and processes that will make China part of your supply chain, BPI China gives you the technical depth and the connections to move faster.Whether you’re a Chinese company looking to expand globally or an international company seeking opportunities in China, this summit is your gateway to innovation, collaboration, and growth in the cell and gene therapy industry.
Why Chinese companies should attend
Make your CMC deal-ready, reach global partners, lead on quality.
China’s innovators are licensing record numbers of assets to global pharma. Helps your teams build the manufacturing and quality story those partners expect.
- Build global-ready CMC: Learn what NMPA, FDA and EMA expect, and what a partner’s due-diligence team will check before a deal closes.
- Solve complex-modality challenges: Compare approaches for bispecifics, ADCs and CAR-T with the companies that have taken them to the clinic and to market.
- Cut cost of goods: See how intensified and continuous processing, and AI on the plant floor, are lowering manufacturing costs.
- Shape China’s standards: Hear directly from NIFDC and Chinese Pharmacopoeia Commission experts on where quality requirements are heading.
Why international companies should attend
Tap into China’s biomanufacturing expertise.
China has become a major source of biologics innovation and manufacturing capacity. BioProcess Internatonal at ChinaBio™ is your fastest route to understanding it.
- Evaluate in-licensing opportunities: Understand the CMC strengths and gaps behind the assets you are considering.
- Build a resilient supply chain: Get practical guidance on dual sourcing, tech transfer and qualifying domestic suppliers after BIOSECURE
- Master regulatory pathways: Learn how NMPA’s faster review timelines and 2025 Pharmacopoeia changes affect your programs.
- Get your name known: Meet China’s process development, manufacturing and quality leaders alongside the ChinaBio™ partnering community.
Explore the complete biopharma ecosystem at ChinaBio™
ChinaBio™ connects the dots across the entire biopharma value chain with specialized summits covering partnerships, R&D innovation, commercial strategy, manufacturing excellence, and more.
As China's biopharma leaders converge in Shanghai for ChinaBio™, this is your opportunity to connect and gain the complete picture of where the industry is.
Book your chosen track but move between all content sessions as you choose.